The effects of a clinical care pathway for schizophrenia: a before and after study in 114 patients.

BACKGROUND The implementation of clinical guidelines in care pathways is being promoted for quality assurance in psychiatry and psychotherapy, as in other medical fields. The achievable benefits are disputed and are generally thought to be small. There have been hardly any studies of the effect of clinical care pathways on the costly inpatient treatment of schizophrenic psychoses. METHODS We conducted a prospective, controlled, before and after study in 114 patients with schizophrenia to determine whether the implementation of a pathway would improve diagnosis and treatment in conformity with published guidelines, and whether there would be any associated improvement in outcome. The patients' course was extensively documented with a number of structural, process-related, and outcome-related variables in the years before and after pathway implementation. Moreover, two different intensive methods of pathway implementation were tested. Data were collected from 2003 to 2005. The primary indicators of outcome quality included pharmacotherapy-related variables and assessments of treatment efficacy by the physicians, the nurses, and the patients themselves. RESULTS After pathway implementation, some diagnostic tests that had been performed only rarely beforehand were performed much more often. The percentage of over- or undermedicated patients, as defined by the treatment pathway, declined markedly. Surprisingly, however, the patients' multidimensionally documented psychopathological course and their subjective judgments of their condition were worse after pathway implementation than before on all four scales that were used to assess these variables. CONCLUSION The implementation of a treatment pathway brought about a robust change in process-related variables. The findings of this study furnish no explanation for the observed decline in treatment efficacy.

[1]  M Loeffler,et al.  AdaptFlow: Protocol-based Medical Treatment Using Adaptive Workflows , 2005, Methods of Information in Medicine.

[2]  J. Kirchner,et al.  Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose. , 2000, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[3]  M. Mäkelä,et al.  Towards evidence-based clinical practice: an international survey of 18 clinical guideline programs. , 2003, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[4]  H. Pfaff,et al.  Physicians' knowledge of and compliance with guidelines: an exploratory study in cardiovascular diseases. , 2011, Deutsches Arzteblatt international.

[5]  T Michael Kashner,et al.  The Texas medication algorithm project: clinical results for schizophrenia. , 2004, Schizophrenia bulletin.

[6]  Gillian D Sanders,et al.  Enabling health care decisionmaking through clinical decision support and knowledge management. , 2012, Evidence report/technology assessment.

[7]  T. Becker,et al.  Effects of implementation of psychiatric guidelines on provider performance and patient outcome: systematic review , 2007, Acta psychiatrica Scandinavica.

[8]  I. Hauth,et al.  Leitlinienkonformität in der Behandlung schizophrener Patienten , 2009, Der Nervenarzt.

[9]  D M Steinwachs,et al.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. , 1998, Schizophrenia bulletin.

[10]  J M Grimshaw,et al.  Effectiveness and efficiency of guideline dissemination and implementation strategies , 2004, International Journal of Technology Assessment in Health Care.

[11]  S. Woods,et al.  Chlorpromazine equivalent doses for the newer atypical antipsychotics. , 2003, The Journal of clinical psychiatry.

[12]  W. Gaebel,et al.  Implementation of a schizophrenia practice guideline: clinical results. , 2008, The Journal of clinical psychiatry.

[13]  G. Laux,et al.  Qualitätsmanagement in der Psychiatrie , 2008, Fortschritte der Neurologie-Psychiatrie.

[14]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[15]  K. Schotte,et al.  A Randomized Controlled Clinical Trial Comparing “Guideline Exposed” and “Guideline Naive” Physicians in Respect to Dosage Selection and Treatment Outcome with Doxepin in Depressive Disorders , 2007, Pharmacopsychiatry.

[16]  M. Crismon,et al.  Evaluation of a schizophrenia medication algorithm in a state hospital. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[17]  F. Dickerson,et al.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. , 2004, Schizophrenia bulletin.